Bisphosphonates and osteoporosis

[1]  J. Bevan,et al.  Effect of etidronate disodium on bone turnover following surgical menopause , 1989, Calcified Tissue International.

[2]  A. Hodsman,et al.  Preliminary observations of a form of coherence therapy for osteoporosis , 1984, Calcified Tissue International.

[3]  H. Canzler,et al.  Results of a stimulatory therapy of low bone metabolism in osteoporosis with (1–38)hPTH and diphosphonate EHDP , 1988, Klinische Wochenschrift.

[4]  F. Melsen,et al.  The effects of etidronate on trabecular bone remodeling in postmenopausal spinal osteoporosis: a randomized study comparing intermittent treatment and an ADFR regime. , 1992, Bone.

[5]  F. Bauss,et al.  BM 21.0955, a potent new bisphosphonate to inhibit bone resorption , 1991, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[6]  W. Mysiw,et al.  Intermittent cyclical etidronate treatment of postmenopausal osteoporosis. , 1990, The New England journal of medicine.

[7]  H. Genant,et al.  Effect of intermittent cyclical etidronate therapy on bone mass and fracture rate in women with postmenopausal osteoporosis. , 1990, The New England journal of medicine.

[8]  J. Reginster,et al.  PREVENTION OF POSTMENOPAUSAL BONE LOSS BY TILUDRONATE , 1989, The Lancet.

[9]  J. Pool,et al.  Cyclic therapy of osteoporosis with neutral phosphate and brief, high‐dose pulses of etidronate , 1989, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[10]  R. Valkema,et al.  Maintained improvement in calcium balance and bone mineral content in patients with osteoporosis treated with the bisphosphonate APD. , 1989, Bone and mineral.

[11]  A. Hodsman.  Effects of cyclical therapy for osteoporosis using an oral regimen of inorganic phosphate and sodium etidronate: a clinical and bone histomorphometric study. , 1989, Bone and mineral.

[12]  L. Avioli,et al.  Coherence therapy does not prevent axial bone loss in osteoporotic women: a preliminary comparative study. , 1988, The Journal of clinical endocrinology and metabolism.

[13]  I. Reid,et al.  PREVENTION OF STEROID-INDUCED OSTEOPOROSIS WITH (3-AMINO-1-HYDROXYPROPYLIDENE)-1, 1-BISPHOSPHONATE (APD) , 1988, The Lancet.

[14]  Bijvoet Ol,et al.  Two modes of action of bisphosphonates on osteoclastic resorption of mineralized matrix. , 1986 .

[15]  P. Boonekamp,et al.  Two modes of action of bisphosphonates on osteoclastic resorption of mineralized matrix. , 1986, Bone and mineral.

[16]  P. Meunier,et al.  Effects of disodium dichloromethylene diphosphonate on bone loss in paraplegic patients. , 1981, The Journal of clinical investigation.

[17]  D. Fink,et al.  SCREENING FOR BREAST CANCER , 1976, The Lancet.

[18]  P. Kelly,et al.  The treatment of osteoporosis with disodium ethane-1-hydroxy-1,1-diphosphonate , 1971 .

[19]  H. Fleisch,et al.  Diphosphonates Inhibit Hydroxyapatite Dissolution in vitro and Bone Resorption in Tissue Culture and in vivo , 1969, Science.